Diabetes Care Volume 38, June 2015
1173
Erratum Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38:394–402
DOI: 10.2337/dc15-er06a
Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, and Uli C. Broedl
In Supplementary Table 3 of the article cited above, for LDL-cholesterol, the adjusted mean (SE) change from baseline [rather than baseline] in difference vs. linagliptin 5 mg for empagliflozin 25 mg/linagliptin 5 mg should be 0.1 (0.1) mmol/L; P 5 0.155. The online version reflects these changes.
ERRATUM
1173
Erratum Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38:394–402
DOI: 10.2337/dc15-er06a
Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, and Uli C. Broedl
In Supplementary Table 3 of the article cited above, for LDL-cholesterol, the adjusted mean (SE) change from baseline [rather than baseline] in difference vs. linagliptin 5 mg for empagliflozin 25 mg/linagliptin 5 mg should be 0.1 (0.1) mmol/L; P 5 0.155. The online version reflects these changes.
ERRATUM
